{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T19:10:52Z","timestamp":1732043452217},"reference-count":31,"publisher":"Institute of Physiology of the Czech Academy of Sciences","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Physiol Res"],"abstract":"<jats:p>Nephrotoxicity as a cause of acute kidney injury (AKI) induced by cisplatin (CP), limits its usefulness as an anticancer agent. Diminazene, an angiotensin converting enzyme 2 activator, exhibited renoprotective properties on rat models of kidney diseases. This research aims to investigate the salutary effect of diminazene in comparison with lisinopril or valsartan in CP-induced AKI. The first and second groups of rats received oral vehicle (distilled water) for 9 days, and saline injection or intraperitoneal CP (6 mg\/kg) on day 6, respectively. Third, fourth, and fifth groups received intraperitoneal injections of CP on day 6 and diminazene (15 mg\/kg\/day, orally), lisinopril (10 mg\/kg\/day, orally), or valsartan (30 mg\/kg\/day, orally), for 9 days, respectively. 24h after the last day of treatment, blood and kidneys were removed under anesthesia for biochemical and histopathological examination. Urine during the last 24 h before sacrificing the rats was also collected. CP significantly increased plasma urea, creatinine, neutrophil gelatinase-associated lipocalin, calcium, phosphorus, and uric acid. It also increased urinary albumin\/creatinine ratio, N-Acetyl-\u03b2-D-Glucosaminidase\/creatinine ratio, and reduced creatinine clearance, as well the plasma concentrations of inflammatory cytokines [plasma tumor necrosis factor\u2013alpha, and interleukin-1beta], and significantly reduced antioxidant indices [catalase, glutathione reductase , and superoxide dismutase].  Histopathologically, CP treatment caused necrosis of renal tubules, tubular casts, shrunken glomeruli, and increased renal fibrosis. Diminazine, lisinopril, and valsartan ameliorated CP-induced biochemical and histopathological changes to a similar extent. The salutary effect of the three drugs used is, at least partially, due to their anti-inflammatory and antioxidant effects. \nKeywords: Cisplatin \u2022 Diminazene \u2022 ACE2 activator \u2022 Lisinopril \u2022 Valsartan \u2022 Acute kidney injury<\/jats:p>","DOI":"10.33549\/physiolres.935210","type":"journal-article","created":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T12:14:40Z","timestamp":1714652080000},"page":"227-237","source":"Crossref","is-referenced-by-count":1,"title":["The Salutary Effects of Diminazene, Lisinopril or Valsartan on Cisplatin \u2013 Induced Acute Kidney Injury in Rats: A Comparative Study"],"prefix":"10.33549","author":[{"given":"YM","family":"Al Suleimani","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Clinical Pharmacy, College of Medicine and Health Sciences, Sultan Qaboos University, P.O. Box 35, Al Khod, 123, Oman. yousufm@squ.edu.om"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"BH","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Manoj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KS","family":"Almashaiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AM","family":"Abdelrahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"19169","published-online":{"date-parts":[[2024,4,30]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Nurul RA, Norhashima AR, Faizah O, Siti BB, Farida H, Seong LT. Protective role of natural products in cisplatin-induced nephrotoxicity. Med Chem 2019;19:1134-1143. https:\/\/doi.org\/10.2174\/1389557519666190320124438","DOI":"10.2174\/1389557519666190320124438"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Per\u0161e M, Ve\u010deri\u0107-Haler \u017d. Cisplatin-induced rodent model of kidney injury: characteristics and challenges. Biomed Res Int. 2018;2018:1462802. https:\/\/doi.org\/10.1155\/2018\/1462802","DOI":"10.1155\/2018\/1462802"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Tang C, Livingston MJ, Safirstein R, Dong Z. Cisplatin nephrotoxicity: new insights and therapeutic implications. Nat Rev Nephrol 2023;19:53-72. https:\/\/doi.org\/10.1038\/s41581-022-00631-7","DOI":"10.1038\/s41581-022-00631-7"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Chappell MC. Biochemical evaluation of the renin-angiotensin system: the good, bad, and absolute? Am J Physiol Heart Circ Physiol 2016;310:H137-52. https:\/\/doi.org\/10.1152\/ajpheart.00618.2015","DOI":"10.1152\/ajpheart.00618.2015"},{"key":"ref4","unstructured":"Achkar TM, McCullough PA, Sutton MG. The renin-angiotensin system and COVID-19: Implications for renal involvement. Kidney 2022;3:173-180."},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Zhang Y, He D, Zhang W, Xing Y, Guo Y, Wang F, Jia J, Yan T, Liu Y, Lin S. ACE Inhibitor benefit to kidney and cardiovascular outcomes for patients with non-dialysis chronic kidney disease stages 3-5: A network meta-analysis of randomised clinical trials. Drugs 2020;80:797-811. https:\/\/doi.org\/10.1007\/s40265-020-01290-3","DOI":"10.1007\/s40265-020-01290-3"},{"key":"ref6","unstructured":"Hill RD, Vaidya PN. Angiotensin II Receptor Blockers (ARB). In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK537027\/"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Velkoska E, Patel SK, Burrell LM. Angiotensin converting enzyme 2 and diminazene: role in cardiovascular and blood pressure regulation. Curr Opin Nephrol Hypertens 2016;25:384-95. https:\/\/doi.org\/10.1097\/MNH.0000000000000254","DOI":"10.1097\/mnh.0000000000000254"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Haber PK, Ye M, Wysocki J, Maier C, Haque SK, Batlle D. Angiotensin-converting enzyme 2-independent action of presumed angiotensin-converting enzyme 2 activators: studies in vivo, ex vivo, and in vitro. Hypertension 2014;63:774-782. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.113.02856","DOI":"10.1161\/hypertensionaha.113.02856"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Abdelrahman AM, Ali BH, Ali H, Manoj P, Al-Suleimani Y. The effect of diminazene, an angiotensin-converting enzyme 2 activator, on adenine-induced chronic kidney disease in rats. Fundam Clin Pharmacol 2023;37:235-244. https:\/\/doi.org\/10.1111\/fcp.12845","DOI":"10.1111\/fcp.12845"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Goru SK, Kadakol A, Malek V, Pandey A, Sharma N, Gaikwad AB. Diminazene aceturate prevents nephropathy by increasing glomerular ACE2 and AT2 receptor expression in a rat model of type1 diabetes. Br J Pharmacol 2017;174:3118-3130. https:\/\/doi.org\/10.1111\/bph.13946","DOI":"10.1111\/bph.13946"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Lassila M, Finckenberg P, Pere AK, Krogerus L, Ahonen J, Vapaatalo H, Nurminen ML. Comparison of enalapril and valsartan in cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on high-sodium diet. Br J Pharmacol 2000;130:1339-1347. https:\/\/doi.org\/10.1038\/sj.bjp.0703422","DOI":"10.1038\/sj.bjp.0703422"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Ali BH, Karaca T, Al Suleimani Y, Al Za'abi M, Al Kalbani J, Ashique M, Nemmar A. The effect of swimming exercise on adenine-induced kidney disease in rats, and the influence of curcumin or lisinopril thereon. PLoS One 2017;12:e0176316. https:\/\/doi.org\/10.1371\/journal.pone.0176316","DOI":"10.1371\/journal.pone.0176316"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Ali BH, Za'abi MA, Karaca T, Suleimani YA, Balushi KA, Manoj P, Ashique M, Nemmar A. Potassium bromate-induced kidney damage in rats and the effect of gum acacia thereon. Am J Transl Res 2018;10:126-137.","DOI":"10.1371\/journal.pone.0176316"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Al Suleimani YM, Abdelrahman AM, Karaca T, Manoj P, Ashique M, Nemmar A, Ali BH. The effect of the dipeptidyl peptidase-4 inhibitor sitagliptin on gentamicin nephrotoxicity in mice. Biomed Pharmacother 2018;97:1102-1108. https:\/\/doi.org\/10.1016\/j.biopha.2017.10.107","DOI":"10.1016\/j.biopha.2017.10.107"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Ali BH, Al-Salam S, Al Husseini IS, Al-Lawati I, Waly M, Yasin J, Fahim M, Nemmar A. Abrogation of cisplatin-induced nephrotoxicity by emodin in rats. Fundam Clin Pharmacol 2013;27:192-200. https:\/\/doi.org\/10.1111\/j.1472-8206.2011.01003.x","DOI":"10.1111\/j.1472-8206.2011.01003.x"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Manni ML, Czajka CA, Oury TD, Gilbert TW. Extracellular matrix powder protects against bleomycin-induced pulmonary fibrosis. Tissue Eng Part A 2011;17:2795-2804. https:\/\/doi.org\/10.1089\/ten.tea.2011.0023","DOI":"10.1089\/ten.tea.2011.0023"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Lu Z, Wu D, Wan, Z, Zhang H, Du Y, Wang G. Diminazene aceturate mitigates cardiomyopathy by interfering with the renin-angiotensin system in a septic rat model. BMC Pharmacol Toxicol 2022;23,44. https:\/\/doi.org\/10.1186\/s40360-022-00584-4","DOI":"10.1186\/s40360-022-00584-4"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Zhang Y, Liu J, Luo JY, et al. Upregulation of angiotensin (1-7)-mediated signaling preserves endothelial function through reducing oxidative stress in diabetes. Antioxid Redox Signal 2015; 23: 880-892. https:\/\/doi.org\/10.1089\/ars.2014.6070","DOI":"10.1089\/ars.2014.6070"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Gjymishka A, Kulemina LV, Shenoy V, Katovich MJ, Ostrov DA, Raizada MK. Diminazene Aceturate Is an ACE2 Activator and a Novel Antihypertensive Drug. FASEB J 2010;24(Suppl 1):1032.3. https:\/\/doi.org\/10.1096\/fasebj.24.1_supplement.1032.3","DOI":"10.1096\/fasebj.24.1_supplement.1032.3"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Shenoy V, Gjymishka A, Jarajapu YP, et al. Diminazene attenuates pulmonary hypertension and improves angiogenic progenitor cell functions in experimental models. Am J Respir Crit Care Med 2013; 187: 648-657. https:\/\/doi.org\/10.1164\/rccm.201205-0880OC","DOI":"10.1164\/rccm.201205-0880oc"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Singh N, Joshi S, Guo L, et al. ACE2\/Ang-(1-7)\/mas axis stimulates vascular repair-relevant functions of CD34+ cells. Am J Physiol Heart Circ Physiol 2015; 309: H1697-H1707. https:\/\/doi.org\/10.1152\/ajpheart.00854.2014","DOI":"10.1152\/ajpheart.00854.2014"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Velkoska E, Patel SK, Griggs K, Pickering RJ, Tikellis C, Burrell LM. Short-term treatment with diminazene aceturate ameliorates the reduction in kidney ACE2 Activity in Rats with Subtotal Nephrectomy. PLoS ONE 2015; 10: e0118758-e0118758. https:\/\/doi.org\/10.1371\/journal.pone.0118758","DOI":"10.1371\/journal.pone.0118758"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Goru SK, Kadakol A, Malek V, Pandey A, Sharma N, Gaikwad AB. Diminazene aceturate prevents nephropathy by increasing glomerular ACE2 and AT2 receptor expression in a rat model of Type 1 Diabetes. Br J Pharmacol 2017; 174: 3118-3130. https:\/\/doi.org\/10.1111\/bph.13946","DOI":"10.1111\/bph.13946"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Asaad GF, Hassan A, Mostafa RE. Anti-oxidant impact of Lisinopril and Enalapril against acute kidney injury induced by doxorubicin in male Wistar rats: involvement of kidney injury molecule-1. Heliyon 2021;15:e05985. https:\/\/doi.org\/10.1016\/j.heliyon.2021.e05985","DOI":"10.1016\/j.heliyon.2021.e05985"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Esmaeeli A, Ebrahimi F, Tanha K, Assadi M, Seyedabadi M. Low-dose angiotensin AT1 receptor \u03b2-arrestin-biased ligand, TRV027, protects against cisplatin-induced nephrotoxicity. Pharmacol Rep 2020;72:1676-1684. https:\/\/doi.org\/10.1007\/s43440-020-00172-5","DOI":"10.1007\/s43440-020-00172-5"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Fang CY, Lou DY, Zhou LQ, Wang JC, Yang B, He QJ, Wang JJ, Weng QJ. Natural products: potential treatments for cisplatin-induced nephrotoxicity. Acta Pharmacol Sin 2021;42:1951-1969. https:\/\/doi.org\/10.1038\/s41401-021-00620-9","DOI":"10.1038\/s41401-021-00620-9"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Shahid F, Farooqui Z, Khan F. Cisplatin-induced gastrointestinal toxicity: An update on possible mechanisms and on available gastroprotective strategies. Eur J Pharmacol 2018;827:49-57. https:\/\/doi.org\/10.1016\/j.ejphar.2018.03.009","DOI":"10.1016\/j.ejphar.2018.03.009"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Ali BH, Al Salam S, Al Suleimani Y, Al Za'abi M, Ashique M, Manoj P, Sudhadevi M, Al Tobi M, Nemmar A. Ameliorative effect of sesamin in cisplatin-induced nephrotoxicity in rats by suppressing inflammation, oxidative\/nitrosative stress, and cellular damage. Physiol Res 2020;69:61-72. https:\/\/doi.org\/10.33549\/physiolres.934142","DOI":"10.33549\/physiolres.934142"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Ali BH, Abdelrahman A, Al Suleimani Y, Manoj P, Ali H, Nemmar A, Al Za'abi M. Effect of concomitant treatment of curcumin and melatonin on cisplatin-induced nephrotoxicity in rats. Biomed Pharmacother 2020;131:110761. https:\/\/doi.org\/10.1016\/j.biopha.2020.110761","DOI":"10.1016\/j.biopha.2020.110761"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Baldissera MD, Gon\u00e7alves RA, Sagrillo MR, Grando TH, Ritter CS, Grotto FS, Brum GF, da Luz SC, Silveira SO, Fausto VP, Boligon AA, Vaucher RA, Stefani LM, da Silva AS, Souza CF, Monteiro SG. Effects of treatment with the anti-parasitic drug diminazene aceturate on antioxidant enzymes in rat liver and kidney. Naunyn Schmiedebergs Arch Pharmacol 2016;389:429-438. https:\/\/doi.org\/10.1007\/s00210-016-1212-z","DOI":"10.1007\/s00210-016-1212-z"}],"container-title":["Physiological Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T12:14:49Z","timestamp":1714652089000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.biomed.cas.cz\/physiolres\/pdf\/2024\/73_227.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,30]]},"references-count":31,"URL":"https:\/\/doi.org\/10.33549\/physiolres.935210","relation":{},"ISSN":["1802-9973","0862-8408"],"issn-type":[{"value":"1802-9973","type":"electronic"},{"value":"0862-8408","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,30]]}}}